AbiVax Poised For 'Transformational' Q2
Key Clinical Readouts Set To Spur Partnering Talks
Q2 promises to be ‘transformational’ for AbiVax, propelled by key readouts for investigational anti-inflammatory, ABX464, and cancer agent, ABX196, but more funds will be needed by year end.
You may also be interested in...
Abivax will test its anti-inflammatory ABX464 in early COVID-19 patients after the small molecule showed it could reduce SARS-CoV-2 viral replication in human lung tissue in addition to its anti-inflammatory and tissue-healing effects.
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.